Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.
Published in Breast cancer research and treatment (01.04.2019)
Published in Breast cancer research and treatment (01.04.2019)
Get full text
Journal Article
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Slamon, D.J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., Sonke, G.S., De la Cruz-Merino, L., Beck, J.T., Ji, Y., Wang, C., Deore, U., Chakravartty, A., Zarate, J.P., Taran, T., Fasching, P.A.
Published in Annals of oncology (01.08.2021)
Published in Annals of oncology (01.08.2021)
Get full text
Journal Article
Web Resource
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
Curigliano, G., Mueller, V., Borges, V., Hamilton, E., Hurvitz, S., Loi, S., Murthy, R., Okines, A., Paplomata, E., Cameron, D., Carey, L.A., Gelmon, K., Hortobagyi, G.N., Krop, I., Loibl, S., Pegram, M., Slamon, D., Ramos, J., Feng, W., Winer, E.
Published in Annals of oncology (01.03.2022)
Published in Annals of oncology (01.03.2022)
Get full text
Journal Article
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
Neven, P, Fasching, P. A, Chia, S, Jerusalem, G, De Laurentiis, M, Im, S.-A, Petrakova, K, Bianchi, G. V, Martín, M, Nusch, A, Sonke, G. S, De la Cruz-Merino, L, Beck, J. T, Zarate, J. P, Wang, Y, Chakravartty, A, Wang, C, Slamon, D. J
Published in Breast cancer research : BCR (31.08.2023)
Published in Breast cancer research : BCR (31.08.2023)
Get full text
Journal Article
Web Resource
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
Rugo, H.S., Diéras, V., Gelmon, K.A., Finn, R.S., Slamon, D.J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D.R., Bhattacharyya, H., Bartlett, C.H.u.a.n.g., Iyer, S., Johnston, S., Ettl, J., Harbeck, N.
Published in Annals of oncology (01.04.2018)
Published in Annals of oncology (01.04.2018)
Get full text
Journal Article
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
HAMIDI, H, LU, M, CHAU, K, ANDERSON, L, FEJZO, M, GINTHER, C, LINNARTZ, R, ZUBEL, A, SLAMON, D. J, FINN, R. S
Published in British journal of cancer (28.10.2014)
Published in British journal of cancer (28.10.2014)
Get full text
Journal Article
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
André, F, Su, F, Solovieff, N, Hortobagyi, G, Chia, S, Neven, P, Bardia, A, Tripathy, D, Lu, Y-S, Lteif, A, Taran, T, Babbar, N, Slamon, D, Arteaga, C L
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]
Curigliano, G., Mueller, V., Borges, V., Hamilton, E., Hurvitz, S., Loi, S., Murthy, R., Okines, A., Paplomata, E., Cameron, D., Carey, L.A., Gelmon, K., Hortobagyi, G.N., Krop, I., Loibl, S., Pegram, M., Slamon, D., Ramos, J., Feng, W., Winer, E.
Published in Annals of oncology (01.07.2023)
Published in Annals of oncology (01.07.2023)
Get full text
Journal Article
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
KONECNY, G. E, GLAS, R, GAO, G, BRUGGE, J, SLAMON, D. J, DERRING, J, MANIVONG, K, QI, J, FINN, R. S, YANG, G. R, HONG, K.-L, GINTHER, C, WINTERHOFF, B
Published in British journal of cancer (17.11.2009)
Published in British journal of cancer (17.11.2009)
Get full text
Journal Article
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
Konecny, Gottfried, Pauletti, Giovanni, Pegram, Mark, Untch, Michael, Dandekar, Sugandha, Aguilar, Zuleima, Wilson, Cindy, Rong, Hong-Mei, Bauerfeind, Ingo, Felber, Margret, Wang, He-Jing, Beryt, Malgorzata, Seshadri, Ram, Hepp, Herrmann, Slamon, Dennis J.
Published in JNCI : Journal of the National Cancer Institute (15.01.2003)
Published in JNCI : Journal of the National Cancer Institute (15.01.2003)
Get full text
Journal Article
FOXA1 represses the molecular phenotype of basal breast cancer cells
Bernardo, G M, Bebek, G, Ginther, C L, Sizemore, S T, Lozada, K L, Miedler, J D, Anderson, L A, Godwin, A K, Abdul-Karim, F W, Slamon, D J, Keri, R A
Published in Oncogene (31.01.2013)
Published in Oncogene (31.01.2013)
Get full text
Journal Article
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer
Davidson, T.M., Lebreton, C.L., Hendricksen, A.E. Wahner, Atkinson, H.J., Larson, M.C., Oberg, A.L., Provencher, D.M., Glaspy, J.A., Karlan, B.Y., Slamon, D.J., Konecny, G.E., Ray-Coquard, I.L.
Published in Gynecologic oncology (01.03.2023)
Published in Gynecologic oncology (01.03.2023)
Get full text
Journal Article
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
KONECNY, G. E, VENKATESAN, N, SLAMON, D. J, PODRATZ, K. C, YANG, G, DERING, J, GINTHER, C, FINN, R, RAHMEH, M, SCHOENBERG FEJZO, M, TOFT, D, JIANG, S-W
Published in British journal of cancer (25.03.2008)
Published in British journal of cancer (25.03.2008)
Get full text
Journal Article
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]
Slamon, D.J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., Sonke, G.S., De la Cruz-Merino, L., Beck, J.T., Ji, Y., Wang, C., Deore, U., Chakravartty, A., Zarate, J.P., Taran, T., Fasching, P.A.
Published in Annals of oncology (01.10.2021)
Published in Annals of oncology (01.10.2021)
Get full text
Journal Article
Web Resource
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1
Ryan, B.M., Konecny, G.E., Kahlert, S., Wang, H.-J., Untch, M., Meng, G., Pegram, M.D., Podratz, K.C., Crown, J., Slamon, D.J., Duffy, M.J.
Published in Annals of oncology (01.04.2006)
Published in Annals of oncology (01.04.2006)
Get full text
Journal Article
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
Pegram, Mark D., Pienkowski, Tadeusz, Northfelt, Donald W., Eiermann, Wolfgang, Patel, Ravi, Fumoleau, Pierre, Quan, Eleonor, Crown, John, Toppmeyer, Deborah, Smylie, Michael, Riva, Alessandro, Blitz, Sandra, Press, Michael F., Reese, David, Lindsay, Mary-Ann, Slamon, Dennis J.
Published in JNCI : Journal of the National Cancer Institute (19.05.2004)
Published in JNCI : Journal of the National Cancer Institute (19.05.2004)
Get full text
Journal Article
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
Michiels, S., Pugliano, L., Marguet, S., Grun, D., Barinoff, J., Cameron, D., Cobleigh, M., Di Leo, A., Johnston, S., Gasparini, G., Kaufman, B., Marty, M., Nekljudova, V., Paluch-Shimon, S., Penault-Llorca, F., Slamon, D., Vogel, C., von Minckwitz, G., Buyse, M., Piccart, M.
Published in Annals of oncology (01.06.2016)
Published in Annals of oncology (01.06.2016)
Get full text
Journal Article
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
Browne, B.C., Crown, J., Venkatesan, N., Duffy, M.J., Clynes, M., Slamon, D., O'Donovan, N.
Published in Annals of oncology (01.01.2011)
Published in Annals of oncology (01.01.2011)
Get full text
Journal Article
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
COBLEIGH, M. A, VOGEL, C. L, SLAMON, D. J, TRIPATHY, D, ROBERT, N. J, SCHOLL, S, FEHRENBACHER, L, WOLTER, J. M, PATON, V, SHAK, S, LIEBERMAN, G
Published in Journal of clinical oncology (01.09.1999)
Published in Journal of clinical oncology (01.09.1999)
Get full text
Journal Article